Literature DB >> 6226926

Vitamin and mineral supplementation in Down's syndrome.

F C Bennett, S McClelland, E A Kriegsmann, L B Andrus, C J Sells.   

Abstract

The claim that large, nonspecific doses of vitamins and minerals improve the performance of mentally retarded children has recently reappeared in both the scientific literature and the public media. This hypothesis was examined in a double-blind, case-control study involving 20 home-reared children with Down's syndrome between 5 and 13 years of age. Children were randomly assigned by matched pairs to either a vitamin/mineral group or placebo group for an 8-month study period. No significant group differences or suggestive trends were found in any tested area of development or behavior, including intelligence (IQ), school achievement, speech and language, and neuromotor function. No group differences in appearance, growth, or health were seen. No support was found for the orthomolecular hypothesis in school-aged children with Down's syndrome.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6226926

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  6 in total

Review 1.  Megavitamin and megamineral therapy in childhood. Nutrition Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1990-11-15       Impact factor: 8.262

Review 2.  Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome.

Authors:  Eric D Hamlett; Heather A Boger; Aurélie Ledreux; Christy M Kelley; Elliott J Mufson; Maria F Falangola; David N Guilfoyle; Ralph A Nixon; David Patterson; Nathan Duval; Ann-Charlotte E Granholm
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

3.  Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial.

Authors:  Jill M Ellis; Hooi Kuan Tan; Ruth E Gilbert; David P R Muller; William Henley; Robert Moy; Rachel Pumphrey; Cornelius Ani; Sarah Davies; Vanessa Edwards; Heather Green; Alison Salt; Stuart Logan
Journal:  BMJ       Date:  2008-02-21

4.  Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model.

Authors:  Jason Lockrow; Annamalai Prakasam; Peng Huang; Heather Bimonte-Nelson; Kumar Sambamurti; Ann-Charlotte Granholm
Journal:  Exp Neurol       Date:  2008-12-10       Impact factor: 5.330

5.  Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis.

Authors:  Aurore Curie; Kathy Yang; Irving Kirsch; Randy L Gollub; Vincent des Portes; Ted J Kaptchuk; Karin B Jensen
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

6.  Effect of leucovorin (folinic acid) on the developmental quotient of children with Down's syndrome (trisomy 21) and influence of thyroid status.

Authors:  Henri Blehaut; Clotilde Mircher; Aimé Ravel; Martine Conte; Veronique de Portzamparc; Gwendael Poret; Françoise Huon de Kermadec; Marie-Odile Rethore; Franck G Sturtz
Journal:  PLoS One       Date:  2010-01-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.